RESMED INC

20 February, 2025

ResMed Reports Strong Q2 Fiscal 2025 Results with EPS of $2.43 and Revenues of $1.28 Billion, Surpassing Estimates and Indicating Robust Growth Potential

ResMed has reported exceptional financial results for the second quarter of fiscal 2025, positioning itself well in the market. The company achieved an adjusted earnings per share (EPS) of $2.43, surp...
Read More

19 February, 2025

ResMed's Strong Financial Performance and Innovation Drive Impressive Growth Prospects in Medical Sector

ResMed Inc. (RMD) continues to stand out in the medical sector with a Zacks Rank of 2 (Buy) and a strong estimated long-term growth rate of 16%. The company has shown resilience, consistently exceedin...
Read More

17 February, 2025

ResMed Posts Strong Q2 Fiscal 2025 Results with $2.43 EPS and $1.28 Billion in Revenues, Outperforming Estimates

ResMed reported robust financial results for the second quarter of fiscal 2025, highlighting its growth potential and strong market position. The company achieved adjusted earnings per share (EPS) of ...
Read More

16 February, 2025

ResMed Posts Strong Q2 Fiscal 2025 Results with $2.43 EPS and $1.28 Billion in Revenues, Outperforming Estimates

ResMed reported robust financial results for the second quarter of fiscal 2025, highlighting its growth potential and strong market position. The company achieved adjusted earnings per share (EPS) of ...
Read More